U.S. markets open in 9 hours 17 minutes
  • Integral Ad Science Appoints Industry Veteran Tom Sharma as Chief Product Officer
    PR Newswire

    Integral Ad Science Appoints Industry Veteran Tom Sharma as Chief Product Officer

    Integral Ad Science (IAS), the global leader in digital ad verification, today announced that Tom Sharma will join the company as Chief Product Officer, effective November 2, 2020. This critical new hire will accelerate IAS's global product expansion, including plans to enhance its industry-leading Connected TV (CTV) solution. Sharma will be based in New York and report directly to IAS CEO, Lisa Utzschneider.

  • Too few companies disclose financial hit from climate change, regulator says
    Reuters

    Too few companies disclose financial hit from climate change, regulator says

    Too few companies specify their prospective financial hit from climate change under a voluntary global disclosure code that needs wider backing from asset managers and others to be fully effective, a global regulatory body said on Thursday. Climate change can reduce the value of assets or subject companies to costs from flooding and other weather-related events, and a body dubbed the Task Force on Climate-related Financial Disclosures (TCFD) in 2017 published a voluntary set of disclosures to help inform investors. The TCFD, set up by the Financial Stability Board (FSB) which coordinates financial rules for G20 countries, said more than 1,500 organisations worldwide had expressed support for TCFD-aligned disclosures to help cut carbon emissions, up 85% since last year's update.

  • Next crop of COVID-19 vaccine developers take more traditional route
    Reuters

    Next crop of COVID-19 vaccine developers take more traditional route

    The handful of drugmakers dominating the global coronavirus vaccine race are pushing the boundaries of vaccine technology. The world will need several different vaccines to fight the COVID-19 pandemic, given the sheer size of global need, variations in effects on different populations, and possible limits of effectiveness in the first crop. Many leading candidates now in final-stage testing are based on new, largely unproven technology platforms designed to produce vaccines at speed.